Last reviewed · How we verify

Lorcaserin manufactured at Kawashima

Eisai Inc. · Phase 1 active Small molecule

Lorcaserin manufactured at Kawashima is a Small molecule drug developed by Eisai Inc.. It is currently in Phase 1 development. Also known as: BELVIQ XR, APD356.

At a glance

Generic nameLorcaserin manufactured at Kawashima
Also known asBELVIQ XR, APD356
SponsorEisai Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lorcaserin manufactured at Kawashima

What is Lorcaserin manufactured at Kawashima?

Lorcaserin manufactured at Kawashima is a Small molecule drug developed by Eisai Inc..

Who makes Lorcaserin manufactured at Kawashima?

Lorcaserin manufactured at Kawashima is developed by Eisai Inc. (see full Eisai Inc. pipeline at /company/eisai).

Is Lorcaserin manufactured at Kawashima also known as anything else?

Lorcaserin manufactured at Kawashima is also known as BELVIQ XR, APD356.

What development phase is Lorcaserin manufactured at Kawashima in?

Lorcaserin manufactured at Kawashima is in Phase 1.

Related